NCT00951132

Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University Hospital, Akershus · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.

Detailed description

Depression is associated with increased risk of cardiovascular disease, in which one possible mechanism is systemic inflammation. Further, patients at high risk of cardiovascular disease, rosuvastatin decreases the risk, especially among patients with increased inflammation. This is a proof-of-concept study to investigate whether the antiinflammatory effect of rosuvastatin is similar in depressive as in patients with cardiovascular disease.

Conditions

• Depression

Interventions

Type	Name	Description
DRUG	rosuvastatin	10mg tablets, once daily in three months
DRUG	Placebo	tablet, once daily, three months

Timeline

• Start date: 2009-09-01
• Primary completion: 2012-12-01
• Completion: 2013-12-01
• First posted: 2009-08-04
• Last updated: 2023-02-02

Locations

1 site across 1 country: Norway